Cardiovascular Diabetology (May 2025)
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
- Oliver Schnell,
- Jaime Almandoz,
- Lisa Anderson,
- Katharine Barnard-Kelly,
- Tadej Battelino,
- Matthias Blüher,
- Luca Busetto,
- Doina Catrinou,
- Antonio Ceriello,
- Xavier Cos,
- Thomas Danne,
- Colin M. Dayan,
- Stefano Del Prato,
- Beatriz Fernández-Fernández,
- Paola Fioretto,
- Thomas Forst,
- James R. Gavin,
- Francesco Giorgino,
- Per-Henrik Groop,
- Igor A. Harsch,
- Hiddo J. L. Heerspink,
- Lutz Heinemann,
- Mahmoud Ibrahim,
- Michel Jadoul,
- Sarah Jarvis,
- Linong Ji,
- Naresh Kanumilli,
- Mikhail Kosiborod,
- Ulf Landmesser,
- Sofia Macieira,
- Boris Mankovsky,
- Nikolaus Marx,
- Chantal Mathieu,
- Barbara McGowan,
- Tatjana Milenkovic,
- Othmar Moser,
- Dirk Müller-Wieland,
- Nikolaos Papanas,
- Dipesh C. Patel,
- Andreas F. H. Pfeiffer,
- Dario Rahelić,
- Helena W. Rodbard,
- Lars Rydén,
- Elke Schaeffner,
- C. Wendy Spearman,
- Alin Stirban,
- Frank Tacke,
- Pinar Topsever,
- Luc Van Gaal,
- Eberhard Standl
Affiliations
- Oliver Schnell
- Forschergruppe Diabetes e. V., Helmholtz Center Munich
- Jaime Almandoz
- Division of Endocrinology, Department of Internal Medicine, University of Texas Southwestern Medical Center
- Lisa Anderson
- Molecular and Clinical Sciences Research Institute, St. George’s University of London
- Katharine Barnard-Kelly
- Southern Health NHS Foundation Trust
- Tadej Battelino
- University Medical Center
- Matthias Blüher
- Helmholtz Institute for Metabolic, Obesity and Vascular Research (HI-MAG) of the Helmholtz Zentrum München at the University of Leipzig and University Hospital Leipzig
- Luca Busetto
- Department of Medicine (DIMED), University of Padova
- Doina Catrinou
- Faculty of Medicine, Ovidius University of Constanta
- Antonio Ceriello
- IRCCS MultiMedica
- Xavier Cos
- DAP Cat Research Group, Foundation University Institute for Primary Health Care Research Jordi Gol i Gorina
- Thomas Danne
- NOVA Medical School
- Colin M. Dayan
- Cardiff University School of Medicine
- Stefano Del Prato
- Interdisciplinary Research Center “Health Science”, Sant’Anna School of Advanced Studies
- Beatriz Fernández-Fernández
- Division of Nephrology and Hypertension, University Hospital Fundación Jiménez Díaz
- Paola Fioretto
- Faculty of Medicine, University of Padova
- Thomas Forst
- CRS Clinical Research Services Mannheim GmbH
- James R. Gavin
- Emory University School of Medicine
- Francesco Giorgino
- Department of Precision and Regenerative Medicine and Ionian Area, University of Bari Aldo Moro
- Per-Henrik Groop
- Department of Nephrology, University of Helsinki and Helsinki University Hospital
- Igor A. Harsch
- Division of Endocrinology and Metabolism, Department of Internal Medicine II, Thuringia Clinic Saalfeld “Georgius Agricola”
- Hiddo J. L. Heerspink
- Department of Clinical Pharmacy and Pharmacology, University Medical Centre Groningen, University of Groningen
- Lutz Heinemann
- Science Consulting in Diabetes GmbH
- Mahmoud Ibrahim
- EDC, Centre for Diabetes Education
- Michel Jadoul
- Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain
- Sarah Jarvis
- General Practitioner
- Linong Ji
- Peking University People’s Hospital
- Naresh Kanumilli
- Manchester University Foundation Trust
- Mikhail Kosiborod
- Department of Cardiovascular Disease, Saint Luke’s Mid America Heart Institute, University of Missouri-Kansas City School of Medicine
- Ulf Landmesser
- Department of Cardiology Angiology and Intensive Care Medicine, Charité Universitätsmedizin Berlin
- Sofia Macieira
- Sciarc GmbH
- Boris Mankovsky
- Depatment of Diabetology, Shupyk National Healthcare University of Ukraine
- Nikolaus Marx
- Clinic for Cardiology, Pneumology, Angiology and Internal Intensive Care Medicine (Medical Clinic I), RWTH Aachen University Hospital
- Chantal Mathieu
- Department of Endocrinology, Catholic University of Louvain
- Barbara McGowan
- Guy’s and St Thomas’ Hospital, Kings College London
- Tatjana Milenkovic
- University Clinic of Endocrinology, Diabetes and Metabolic Diseases
- Othmar Moser
- Institute of Sports Science, University of Bayreuth
- Dirk Müller-Wieland
- Department of Medicine I, University Hospital Aachen
- Nikolaos Papanas
- Diabetes Centre-Diabetic Foot Clinic, Second Department of Internal Medicine, Democritus University of Thrace
- Dipesh C. Patel
- Royal Free London, University College London
- Andreas F. H. Pfeiffer
- Department of Endocrinology and Metabolic Diseases, Charité Universitätsmedizin Berlin, Campus Benjamin Franklin
- Dario Rahelić
- Vuk Vrhovac University Clinic for Diabetes, Endocrinology and Metabolic Diseases at Merkur University Hospital
- Helena W. Rodbard
- Endocrine and Metabolic Consultants
- Lars Rydén
- Department of Medicine K2, Karolinska Institute
- Elke Schaeffner
- Institute of Public Health, Charité Universitätsmedizin Berlin
- C. Wendy Spearman
- Division of Hepatology, Department of Medicine, Faculty of Health Sciences, University of Cape Town
- Alin Stirban
- Asklepios Klinik Birkenwerder
- Frank Tacke
- Department of Hepatology and Gastroenterology, Charité - Universitätsmedizin Berlin, Campus Virchow-Klinikum and Campus Charité Mitte
- Pinar Topsever
- Department of Family Medicine, Acıbadem Mehmet Ali Aydınlar University School of Medicine
- Luc Van Gaal
- Department of Endocrinology-Diabetology and Metabolism, Antwerp University Hospital
- Eberhard Standl
- Forschergruppe Diabetes e. V., Helmholtz Center Munich
- DOI
- https://doi.org/10.1186/s12933-025-02700-0
- Journal volume & issue
-
Vol. 24,
no. 1
pp. 1 – 20
Abstract
Abstract The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20–21, 2025 ( http://www.cvot.org ).
Keywords
